Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus

Systemic Lupus Erythematosus

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

Rheumatology (Oxford)

Nakanishi E, Matsushita M, Minowa K, Tada K, Kawamoto T, Kusaoi M, Amano H, Kon T, Morimoto S, Ikeda K, Suzuki S, Nozawa K, Yang KS, Matsudaira R, Katagiri A, Tsushima H, Urasaki W, Nojiri S, Yamaji K, Tamura N

doi: 10.1093/rheumatology/keaf349

T Cells

BK Virus-Specific T Cell Response Associated with HLA Genotypes, RhD Status, and CMV or EBV Serostatus in Healthy Donors for Optimized Cell Therapy

J Clin Immunol

Mora-Buch R, Tomás-Marín M, Pasamar H, Enrich E, Peña-Gómez C, Rudilla F

doi: 10.1007/s10875-025-01901-2

Systemic Lupus ErythematosusSystemic Sclerosis

Menopausal hormone therapy and the risk of systemic lupus erythematosus and systemic sclerosis: a population-based nested case-control study

Rheumatology (Oxford)

Patasova K, Dehara M, Mantel Ä, Bixo M, Arkema E, Holmqvist M

doi: 10.1093/rheumatology/keaf004

Systemic Lupus Erythematosus

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

Arthritis Res Ther

Kojima K, Ichinose K, Umeda M, Shimizu T, Sato S, Suzuki T, Nakashima Y, Okada A, Horai Y, Fujikawa K, Aramaki T, Miyashita T, Furuyama M, Matsuoka N, Kawakami A

doi: 10.1186/s13075-025-03581-0

Systemic Lupus Erythematosus

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

N Engl J Med

van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, Hu J, Huang C, Zhao J, Huang C, Mo H, Wei W, Lu F, Li J, Zhao D, Wang W, Li L, Zuraw Q, Wang X, Wang X, Fang J, Zhang F, 18C010 Trial Investigators

doi: 10.1056/NEJMoa2414719

Systemic Lupus Erythematosus

Factors and outcomes related to clinical inertia in systemic lupus erythematosus: a multicentre LUNA cohort study

Rheumatology (Oxford)

Miyake H, Kida T, Yoshimi R, Michizu Y, Nishimura K, Sada KE, Miyawaki Y, Matsuo Y, Ohno S, Kajiyama H, Sato S, Shimojima Y, Fujiwara M, Takatani A, Onishi T, Katsushima M, Ida T, Umekita K, Nakano H, Ikeda K, Ichinose K, Onishi A

doi: 10.1093/rheumatology/keaf504

Psoriatic Arthritis

CD3+ immune cell endotypes are associated with PsA disease phenotype and response to advanced therapy: an integrated mass cytometry and proteomics cohort study

Ann Rheum Dis

Eder L, Dang S, Caucheteux SM, Li X, Thib S, Ganatra D, Ritchlin C, Jurisica I, Piguet V, Diao L, Chandran V

doi: 10.1016/j.ard.2025.10.011

Systemic Lupus Erythematosus

Predictors of damage accrual by organ domain in systemic lupus erythematosus

Rheumatology (Oxford)

Kandane-Rathnayake R, Zolio L, Choi J, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Chan M, Kikuchi J, Takeuchi T, Oon S, Bae SC, Goldblatt F, O'Neill S, Ng KPL, Law A, Basnayake B, Tugnet N, Kumar S, Tee C, Tee M, Tanaka Y, Lau CS, Hoi A, Nikpour M, Morand EF

doi: 10.1093/rheumatology/keaf610

Systemic Lupus Erythematosus

Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort

Arthritis Res Ther

Kandane-Rathnayake R, Louthrenoo W, Lau CS, Hamijoyo L, Cho J, Lateef A, Luo SF, Wu YJ, Navarra S, Zamora L, Li Z, Chen YH, Oon S, Chan M, Sockalingam S, Hao Y, Zhang Z, Bae SC, Kikuchi J, Takeuchi T, Katsumata Y, Basnayake B, Goldblatt F, O'Neill S, Pek Ling Ng K, Tugnet N, Sapsford M, Poh YJ, Tee C, Tee M, Ohkubo N, Lefeber AO, Shisha T, Tanaka Y, Golder V, Nikpour M, Hoi A, Gergely P, Morand E

doi: 10.1186/s13075-025-03622-8

Related content

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

BK Virus-Specific T Cell Response Associated with HLA Genotypes, RhD Status, and CMV or EBV Serostatus in Healthy Donors for Optimized Cell Therapy

Menopausal hormone therapy and the risk of systemic lupus erythematosus and systemic sclerosis: a population-based nested case-control study

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

Factors and outcomes related to clinical inertia in systemic lupus erythematosus: a multicentre LUNA cohort study

CD3+ immune cell endotypes are associated with PsA disease phenotype and response to advanced therapy: an integrated mass cytometry and proteomics cohort study

Predictors of damage accrual by organ domain in systemic lupus erythematosus

Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort